Longitudinal changes in body fat and metabolic complications in young people with perinatally acquired HIV

Abstract

AbstractBackgroundThe role of body fat on metabolic complications remains poorly understood in young people living with perinatally acquired HIV (YPHIV).ObjectiveOur objective was to assess the association of changes in adiposity over 2 years with metabolic outcomes in YPHIV.MethodsThe PHACS Adolescent Master Protocol (AMP) study enrolled YPHIV from 2007 to 2009 across 15 US sites, including Puerto Rico. We included YPHIV aged 7–19 years with body composition data assessed by whole‐body dual‐energy X‐ray absorptiometry (DXA) at baseline and 2 years later. Metabolic outcomes included homeostatic model assessment of insulin resistance (HOMA‐IR) and non‐high‐density lipoprotein cholesterol (non‐HDL‐C). We fitted linear regression models to assess the association of increase in body fat over 2 years with metabolic outcomes at years 2 and 3.ResultsIn all, 232 participants had a second DXA and either HOMA‐IR or non‐HDL‐C measured at year 2. Participant characteristics at the first DXA were: age 12 years (9–14) [median (Q1–Q3)], 69% Black, and median CD4 count 714 cells/μL; 70% with HIV RNA <400 copies/mL. In adjusted analyses for every 1% increase in body fat from baseline to year 2, HOMA‐IR was higher by 1.03‐fold at year 3 (95% CI: 1.00, 1.05). We observed that for every 1% increase in body fat from baseline to year 2, non‐HDL‐C was 0.72 mg/dL higher at year 2 (95% CI: −0.04–1.49) and 0.81 mg/dL higher at year 3 (95% CI: −0.05–1.66).ConclusionsIncreases in adiposity over time may lead to downstream decreased insulin sensitivity and dyslipidaemia in YPHIV.